JP2024506530A5 - - Google Patents

Info

Publication number
JP2024506530A5
JP2024506530A5 JP2023545262A JP2023545262A JP2024506530A5 JP 2024506530 A5 JP2024506530 A5 JP 2024506530A5 JP 2023545262 A JP2023545262 A JP 2023545262A JP 2023545262 A JP2023545262 A JP 2023545262A JP 2024506530 A5 JP2024506530 A5 JP 2024506530A5
Authority
JP
Japan
Prior art keywords
group
alkyl
aryl
heterocyclyl
hydrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023545262A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506530A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/051650 external-priority patent/WO2022157392A1/en
Publication of JP2024506530A publication Critical patent/JP2024506530A/ja
Publication of JP2024506530A5 publication Critical patent/JP2024506530A5/ja
Pending legal-status Critical Current

Links

JP2023545262A 2021-01-25 2022-01-25 フェロトーシス制御性細胞死の阻害剤としてのインドール、6-および7-アザインドール誘導体の使用 Pending JP2024506530A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21305085 2021-01-25
EP21305085.9 2021-01-25
PCT/EP2022/051650 WO2022157392A1 (en) 2021-01-25 2022-01-25 Use of indole, 6- and 7-azaindole derivatives as inhibitors of ferroptosis regulated cell death

Publications (2)

Publication Number Publication Date
JP2024506530A JP2024506530A (ja) 2024-02-14
JP2024506530A5 true JP2024506530A5 (cg-RX-API-DMAC7.html) 2025-01-31

Family

ID=74553738

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023545262A Pending JP2024506530A (ja) 2021-01-25 2022-01-25 フェロトーシス制御性細胞死の阻害剤としてのインドール、6-および7-アザインドール誘導体の使用

Country Status (6)

Country Link
US (1) US20240116923A1 (cg-RX-API-DMAC7.html)
EP (1) EP4281070A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024506530A (cg-RX-API-DMAC7.html)
CN (1) CN117529317A (cg-RX-API-DMAC7.html)
CA (1) CA3205853A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022157392A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4626414A1 (en) 2022-12-02 2025-10-08 Seabelife Synergistic combinations of regulated necrosis inhibitors with n-acetylcysteine
EP4791394A1 (en) 2023-10-12 2026-08-19 Seabelife Method and kit for inducing cell differentiation, and regulated necrotic cell death inhibitor for use for regenerating damaged tissues
WO2025206255A1 (ja) * 2024-03-29 2025-10-02 富士フイルム株式会社 被験物質の評価方法および被験物質の評価キット

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140164A1 (en) * 2010-05-06 2011-11-10 Merck Sharp & Dohme Corp. Aza-indole derivatives useful as modulators of faah
WO2017054216A1 (zh) * 2015-10-01 2017-04-06 史利利 电磁炉及线圈盘
WO2017064217A1 (en) * 2015-10-13 2017-04-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Sibiriline derivatives for use for preventing and/or treating disorders associated with cellular necroptosis
EP3362450B1 (en) * 2015-10-13 2020-07-01 Institut National de la Sante et de la Recherche Medicale (INSERM) N1- and n7-substituted sibiriline derivatives and their use as inhibitors of cellular necroptosis
WO2019106434A1 (en) * 2017-12-01 2019-06-06 Collaborative Medicinal Development Pty. Ltd. Heterobicyclic aromatic derivatives for the treatment of ferroptosis-related disorders
EP3887351A4 (en) * 2018-11-27 2022-11-02 The Trustees of Columbia University in the City of New York COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATION OF FERROPTOSE AND TREATMENT OF EXCITOTOXIC DISORDERS
CN113631535B (zh) * 2019-03-11 2024-04-12 协同医药发展有限公司 治疗铁死亡相关紊乱的杂芳基和双杂环芳基衍生物

Similar Documents

Publication Publication Date Title
AU2018202865B2 (en) Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
JP2010502675A5 (cg-RX-API-DMAC7.html)
JP2020523351A5 (cg-RX-API-DMAC7.html)
ES2405054T3 (es) Derivados de pirazol-1,2,4-oxadiazol como agonistas de esfingosina-1-fosfato
JP5576485B2 (ja) 新生物疾患又は自己免疫疾患を処置するためのプロドラッグとしてのフラザノベンゾイミダゾール
JP2010540593A5 (cg-RX-API-DMAC7.html)
JP2013526494A5 (cg-RX-API-DMAC7.html)
JP2007515432A5 (cg-RX-API-DMAC7.html)
JP6535758B2 (ja) 芳香族アミド誘導体の製造方法
ES2296162T3 (es) Derivados de alquilpiperazin- y alquilhomopiperazin- carboxilatos, su preparacion y su aplicacion como inhibidores de la enzima faah.
TN2010000256A1 (en) Organic compound
PL200955B1 (pl) Przeciwwirusowa kompozycja farmaceutyczna i jej zastosowanie oraz zawierająca azot heterocykliczna pochodna karboksamidu
JP2006513221A5 (cg-RX-API-DMAC7.html)
CA2496844A1 (en) Dihydropyridine derivatives for use as human neutrophil elastase inhibitors
JP2006528980A5 (cg-RX-API-DMAC7.html)
JP2008517915A5 (cg-RX-API-DMAC7.html)
ES2548258T3 (es) Compuestos de oxadiazol sustituidos y su uso como agonistas de S1P1
AR054787A1 (es) Derivados de piperidinas utiles como antagonistas de histamina h3
TW200806652A (en) N-hydroxyacrylamide compounds
JP2013542267A5 (cg-RX-API-DMAC7.html)
JP2022533939A5 (cg-RX-API-DMAC7.html)
CZ289376B6 (cs) Substituované benzamidiny, způsob jejich výroby a farmaceutický prostředek s jejich obsahem
EP4457214A2 (en) Dimethyltryptamine analogues as nitric oxide delivery drugs
CA2666975C (en) Aminopyrazole derivatives, process for the preparation thereof, and composition for preventing or treating ischemic diseases containing the same
JP2022552019A5 (cg-RX-API-DMAC7.html)